Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom

Clinical Therapeutics

Volumn 31, Issue PART. 2, 2009, Pages 2398-2415

  Guest, Julian F ^a,b   Smith, Helen ^a   Sladkevicius, Erikas ^a   Jackson, Graham ^c  

^a CATALYST Health Economics Consultants   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

cladribine; cost; cost effectiveness; hairy cell leukemia; pentostatin; rituximab

Indexed keywords

CLADRIBINE; PENTOSTATIN; RITUXIMAB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HAIRY CELL LEUKEMIA; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH SERVICE; NEUTROPENIA; NONBIOLOGICAL MODEL; PREDICTION; QUALITY ADJUSTED LIFE YEAR; SPLENECTOMY; TREATMENT OUTCOME; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; CLADRIBINE; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; LEUKEMIA, HAIRY CELL; MODELS, ECONOMIC; PENTOSTATIN; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 74549184747     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.016     Document Type: Article

References (38)

1. Raghavan E., Brecher M.L., Johnson D.H., et al. Textbook of Uncommon Cancers. 3rd ed (2006), Wiley, Hoboken, NJ
2. Else M., Dearden C.E., Matutes E., et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145 (2009) 733-740
3. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev. 32 (2006) 365-376
4. Ravandi F., Jorgensen J.L., O'Brien S.M., et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 107 (2006) 4658-4662
5. Cervetti G., Galimberti S., Andreazzoli F., et al. Rituximab as treatment for minimal residual disease in hairy cell leukae- mia: Extended follow-up. Br J Haematol 143 (2008) 296-298
6. Aurer I., Mitrović Z., Kovacević-Metelko J., et al. Treatment of hairy cell leukemia with cladribine [in Croatian]. Lijec Vjesn 129 (2007) 80-83
7. Bilwani F., Usman M., Adil S.N., et al. Hairy cell leukemia: Clinical presentation and long term follow up after treatment with 2-chlorodeoxyadenosine (2-CdA). J Pak Med Assoc 55 (2005) 212-213
8. Chadha P., Rademaker A.W., Mendiratta P., et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): Long-term follow-up of the Northwestern University experience. Blood. 106 (2005) 241-246
9. Cheson B.D., Sorensen J.M., Vena D.A., et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: A report of 979 patients. J Clin Oncol 16 (1998) 3007-3015
10. Fayad L.E., Estey E., Thomas D., et al. Treatment of hairy cell leukemia with cladribine (2CDA): Long-term follow-up at M.D. Anderson Cancer Center. Blood 98 (2001) 635a Abstract no. 2659
11. Füreder W., Weltermann A., Chott A., et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine). Wien Klin Wochenschr 111 (1999) 1027-1030
12. Goodman G.R., Burian C., Koziol J.A., and Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21 (2003) 891-896
13. Jehn U., Bartl R., Dietzfelbinger H., et al. An update: 12-Year follow- up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 18 (2004) 1476-1481
14. Robak T., Błasińska-Morawiec M., Bloriski J., et al. 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-Year experience in Poland. Eur J Haematol 62 (1999) 49-56
15. Saven A., Burian C., Koziol J.A., and Piro L.D. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92 (1998) 1918-1926
16. Tallman M.S., Hakimian D., Variakojis D., et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood. 80 (1992) 2203-2209
17. von Rohr A., Schmitz S.F., Tichelli A., et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: A phase II study. Ann Oncol. 13 (2002) 1641-1649
18. Zinzani P.L., Magagnoli M., Bendandi M., et al. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Haematologica 85 (2000) 922-925
19. Zinzani P.L., Tani M., Marchi E., et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 89 (2004) 309-313
20. Rafel M., Cervantes F., Beltrán J.M., et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: Results of a Spanish collaborative study of 80 patients. Cancer 88 (2000) 352-357
21. Flinn I.W., Kopecky K.J., Foucar M.K., et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 96 (2000) 2981-2986
22. Maloisel F., Benboubker L., Gardembas M., et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 17 (2003) 45-51
23. Ribeiro P., Bouaffia F., Peaud P.Y., et al. Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer. 85 (1999) 65-71
24. Johnston J.B., Eisenhauer E., Wainman N., et al. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): A National Cancer Institute of Canada study. Semin Oncol 27 Suppl 5 (2000) 32-36
25. Nieva J., Bethel K., and Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 102 (2003) 810-813
26. Thomas D.A., O'Brien S., Bueso-Ramos C., et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 102 (2003) 3906-3911
27. Hagberg H., and Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 115 (2001) 609-611
28. Else M., Osuji N., Forconi F., et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/ refractory hairy cell leukemia. Cancer. 110 (2007) 2240-2247
29. Jehn U., Bartl R., Dietzfelbinger H., et al. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Ann Hematol 78 (1999) 139-144
30. Cervetti G., Galimberti S., Andreazzoli F., et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 73 (2004) 412-417
31. Office for National Statistics. Mortality statistics. Deaths registered in 2007. http://www.statistics.gov.uk/downloads/theme_health/DR2007/DR_07_2007.pdf Accessed June 12, 2009
32. Morris S., Devlin N., and Parkin D. Economic Analysis in Health Care (2007), Wiley & Sons, Chichester, UK
33. Hammerschmidt T., Zeitler H.P., Gulich M., and Leidl R. A comparison of different strategies to collect standard gamble utilities. Med Decis Making 24 (2004) 493-503
34. Department of Health. NHS reference costs 2008/09: Collection guidance. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_095859 Accessed June 12, 2009
35. Surelines Limited. The Drug Tariff - Previous Editions. http://www.drugtariff.com Accessed June 12, 2009
36. British National Formulary. http://bnf.org/bnf Accessed June 12, 2009
37. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (reference N1618). http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf Accessed August 6, 2003
38. Zenhäusern R., Simcock M., Gratwohl A., et al., Swiss Group for Clinical Cancer Research (SAKK). Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematologica 93 (2008) 1426-1428